A Phase 2 interventional study of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg in Digital Osteoarthritis or Rheumatoid Arthritis, sponsored by Centre Jean Perrin. Not yet recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-20.
Sponsored by Centre Jean Perrin · Phase 2, Interventional, and Diagnostic
Among 357 studies in Arthritis, Rheumatoid with a site in France — 42 open to participants now, 62 under way, 6 of them phase 3. Arthritis, Rheumatoid · France.
Among the 357 studies in Arthritis, Rheumatoid with a site in France, this one is the 152nd largest by planned enrollment of the 222 interventional ones that give a count, is one of 9 that started in 2026, is one of 33 in phase 2, reaches primary completion later than 41 of the 61 other live ones, and was the 355th registered.
3,332 studies on the registry are indexed under Arthritis, Rheumatoid; 443 are open to participants now.
Browse Arthritis, Rheumatoid studies →42 of the 357 studies in Arthritis, Rheumatoid with a site in France are open now. Recruiting first, the newest first:
University Hospital, Montpellier · Sites in France
Assistance Publique - Hôpitaux de Paris · Sites in France
Centre Hospitalier Universitaire de Saint Etienne · Sites in France
University Hospital, Tours · Sites in France
GlaxoSmithKline · Sites in France, Argentina, Brazil and 6 more countries
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
357 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 37 · Phase 3 75 · Phase 4 37
First in 2000; this study’s year is marked. 9 started in 2026.
This study's planned enrollment of 80 is below the median of 96 across 2,220 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 167 across the 222 interventional studies, 271 across the 134 observational. Of the 261 that completed or were terminated, 99 (38%) have results posted.
This tab as a report to print or save as PDF → With an account.
174 of 357 have an industry lead sponsor. The 10 most frequent:
Centre Jean Perrin is the lead sponsor of 55 studies on the registry; 8 are open to participants now.
Centre Jean Perrin has 1 study filed under Arthritis, Rheumatoid — fewer than ten, so there is no comparison to draw.
16 of the studies in Arthritis, Rheumatoid with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05428488Phase 3University Hospital, MontpellierEfficacy of a Sequential Treatment Strategy in Rheumatoid Arthritis | 2026-11 |
| NCT04870203Phase 3University Hospital, BordeauxCombination of Baricitinib and Anti-TNF in Rheumatoid Arthritis | 2027-03 |
| NCT07321340Centre Hospitalier Universitaire de Saint EtienneInsole Optimization for Rheumatoid Arthritis Patients | 2026-11 |
| NCT06235645University Hospital, ToursdEtection of rheumAtoid aRthritis - Interstitial Lung dIseasE by Thoracic ultRasound | 2026-11 |
| NCT04292067Assistance Publique - Hôpitaux de ParisCharacterisation of Intestinal Microbiota of Patients With Spondyloarthritis or Rheumatoid Arthritis | 2026-11 |
Among the 357 studies in Arthritis, Rheumatoid with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study is a phase Ii clinical trial aimed to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group ; digital osteoarthrosis and rheumatoid arthritis
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
RA Group:
Group DOA:
Exclusion Criteria:
RA Group:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Karnofsky performance status (KPS)
A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.
Studies often ask for 60 or 70 and above. Your doctor gives the score.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colours or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
Drug: 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg
1 intravenous injection of 99mTc-NTP 15-5 at a diagnostic activity of 15 MBq/kg (D0)
to evaluate the performance of 99mTc-NTP 15-5 to identify a pathological hand joint in each group: digital osteoarthritis (DOA) and rheumatoid arthritis (RA)
The diagnostic accuracy of 99mTc-NTP 15-5 imaging in detecting an abnormal joint among the 15 joints of the hands. The scintigraphic analysis of the joints will be visual, blinded to the pathology, and binary in nature. A joint will be considered pathological on 99mTc-NTP 15-5 in the event of abnormal tracer uptake, compared to joints with physiological uptake. The diagnosis of a pathological joint (gold standard) will be based on a composite radiological-clinical analysis.
Time frame: 2 hour after injection
to evaluate the diagnostic performance of 99mTc-NTP 15-5 for differential diagnosis between DAO and RA.
Performance measures of 99mTc-NTP 15-5 imaging for distinguishing between DAO and RA. Readers will classify the scintigrams as DAO or RA based on the uptake pattern. A consensus will be sought in cases of disagreement. The gold standard will be the diagnosis determined by radioclinical analysis.
Time frame: 2 hours after injection of 99mTc-NTP 15-5
to evaluate the performance of 99mTc-NTP imaging 15-5 by joint group in each pathology.
Performance measures of 99mTc-NTP 15-5 imaging to detect an affected joint complex
Time frame: 2 hours after injection
to determine the prevalence of joint damage by pathology according to the scintigraphic method and the radioclinical method
The proportion of joints classified as pathological, according to the scintigraphic method and the radioclinical method
Time frame: 2 hours after injection
To quantitatively analyze the fixation of 99mTc-NTP 15-5 on the hand joints, in each pathology.
measurements of the joint/radial diaphysis ration (99mTc-NTP 15-5A/D), determined by semi-automatic contouring joint interfaces on tomoscintigraphic images and manually traced spherical region of interest on radial diaphyses.
Time frame: 2 hours after injection
to evaluate the inter-observer reproducibility of visual and quantitative readings
Inter-observer reproducibility measures: Cohen's kappa coefficient for visual readings (before to consensus) and intra-class correlation coefficient (ICC) for quantitative readings.
Time frame: 2 hours after injection
to describe the fixation of 99mTc-NTP 15-5 on skeletal joints other than hand joints, based on visual analysis.
All skeletal joints other than the hands will be rated by a score : 0: no fixation, 1: fixation \< adjacent diaphysis, 2: fixation = adjacent diaphysis, 3: fixation \> adjacent diaphysis.
Time frame: 2 hours after injection
to evaluate the tolerance of 99mTc-NTP 15-5.
Adverse events (AEs) assessed according to the NCI-CTCAE V5.0 criteria and associated with 99mTc-NTP 15-5 occurring within the week following the injection.
Time frame: during 1 week after injection of 99mTc-NTP 15-5
Plan to share: Undecided
No publications or documents are linked to this record.
Start is estimated for Oct 2026; primary completion for Jul 2028, 21 months later.
Of 42 non-industry phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 49. This study's planned 21 months is below that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
Start moved once since we started tracking on Sep 25, 2026: Aug 2026 → Oct 2026, on Oct 20, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Jean Perrin